Market Cap 447.62B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 23.86
Forward PE 17.03
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 52,635,000
Avg Vol 7,227,618
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 100%
Beta 0.32
Analysts Strong Sell
Price Target $250.97

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Pravo_Koirala
Pravo_Koirala Jun. 28 at 4:34 PM
📊 $ABBV — WEDGE BREAK ON A VOLUME EXPLOSION | 1W Weekly close $253.35, +𝟭𝟳% on the week. This is a structural break, not a drift. 💥 THE VOLUME TELL 𝟴𝟳.𝟱𝗠 shares — the largest volume bar on the entire chart, by a wide margin. A breakout this size on volume this heavy is the confirmation you want. Wedge breaks that fail usually fail on weak volume. This one didn't. 🔓 THE BREAK Price broke clean out of the descending consolidation wedge (converging trendlines off the Oct-2025 $239 high). The candle cleared: ▪ the wedge upper rail ▪ the CHoCH ▪ the Weak High (~$253) ▪ into PREMIUM (above the 1.236 fib / $258 zone) 🪞 Structure flipped. Equilibrium reclaimed, premium entered, momentum confirming. 📐 THE MEASURED MOVE Wedge height ≈ $50 (range low ~$188 → high ~$239). Projected from the ~$253 breakout → ~$𝟯𝟬𝟯. The kicker: that lines up almost exactly with the 𝟭.𝟳𝟴𝟲 fib ($303.11) AND your $302.98 horizontal. Measured move + fib extension agree = the target isn't arbitrary. That's the confluence that matters. 📈 THE PATH ▪ Next resistance: 1.236 $258 → 1.382 $270 → 1.5 $280 → 1.618 $289 → 𝗧𝗔𝗥𝗚𝗘𝗧 1.786 $303 ▪ RSI 67, rising, crossed its signal — momentum behind it, NOT yet overbought (sub-70 leaves room) 🪞 Clean ladder of fib resistance into $303. Each level is a checkpoint, not a wall — but watch $258 (premium entry) for the first pause. 🛡 INVALIDATION A weekly close back INSIDE the wedge / below the breakout (~$240, the prior range high) negates it. That's the line — below it, the break failed and it's a fakeout retest. 🪞 THE READ This is a textbook setup: multi-month wedge, explosive volume break, measured move and fib extension agreeing on ~$303, RSI confirming with room left. The volume is what separates this from a fade — 87M doesn't show up on noise. I want to see it HOLD above the breakout (~$240) on any pullback; a retest that holds is the highest-quality entry. Don't chase the +17% candle extended — let it confirm the breakout as support, then ride the ladder to $303. ⚔ Volume confirmed the break. Measured move = $303. Let it
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Jun. 28 at 4:12 PM
$ABCL i think its more due to Tcell work with $ABBV but I’m sure $JAZZ saw promise with 635 and 575
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 28 at 2:21 AM
$RVMD $SLS $ABBV $MRK Part 4. Merck & Co. (MRK) held advanced acquisition talks to buy Revolution Medicines (RVMD) for roughly $28 billion to $32 billion. However, the deal fell apart in late January 2026 when the two companies could not agree on a final purchase price. Earlier in January 2026, AbbVie (ABBV) was also rumored by the Wall Street Journal to be nearing a deal to acquire Revolution Medicines.$RVMD MC now is $39 Billion any big pharmaceutical have to pay close to $70 Billion to buy them out. I don’t think big pharmaceutical will make the same mistake by trying to tame the$SLS Beast and bidding war is here now before the whole world find out about the one ☝️ and only off the shelf, 0 Toxicity platform GPS with Ad Infinitum dosage CURATIVE cancer platform that can make the most lethal cancers on the planet Dormant and further CURATIVE. I wouldn’t be surprised if we get a T1 halt on Sellas one of these days and company is BO outright. ✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 28 at 12:59 AM
$SLS With the 80th Event Now Truly Imminent, after 5 years - the Share Price / Market Action Sure is doing what you would expect -if- the people* who really understand the drug space are confident in Gps Success. * $ABBV $RHHBY who own the Azacitidine Venetoclax - BAT for Control Arm Patients * Fund Analysts Buying the Share Price Up - Paying Attention to every Last Scrap of Published Trial Data and any information relative and pertinent - etc., etc., etc. ie BAT Failing 3 AML Remission Maintenance Trials - Gps Proven Effective in 2 Phase 2 AML Remission Maintenance trials w 2x and 4x+ Statistically Significant Results - IDMC UNBLINDING ACTUAL Phase 3 MOS and Immune Response Data - 80% IR in the P3 / vs 64% in the P2 - IR is Dir Correlated w Survival. Smarter Money than US Knows.
0 · Reply
KryptonResearch
KryptonResearch Jun. 27 at 10:14 PM
While markets are extremely focused on the inputs to the AI trade (and for good reason, as this is where the capital is flowing at the present moment). We take a look at the flip side of the AI trade. Those using AI to accelerate their businesses. Today’s investment is one of our favorites. A great business and revolutionary technology, but more importantly, one that is going to transform the lives of billions. $LLY $NVO $ABBV $PFE $JNJ Take a read: https://kryptonresearch.substack.com/p/blood-money
0 · Reply
FibonacciTrader_
FibonacciTrader_ Jun. 27 at 10:03 PM
Rotation is doing exactly what it usually does late-cycle- money stops chasing momentum and starts hiding in defensives with visible cash flows. This week the tape flipped hard: $ABBV +17% | pharma leadership catching bid on defensive + yield rotation $MRK +13% | large-cap healthcare strength as risk appetite fades $JNJ +12% | classic safety trade back in favor $DHR +11% | life sciences tools seeing steady institutional demand $LLY +10% | still strong structurally, but now part of broader defensive bid Meanwhile semis are cooling as AI beta unwinds from stretched positioning. This isn’t “AI is dead” pricing. It’s capital rotating from narrative to stability. When healthcare leads and semis lag, the market is telling you one thing: risk is being reduced, not added
0 · Reply
bzb711
bzb711 Jun. 27 at 10:03 PM
$ABBV Now money flows to Healthcare from Tech, that’s why investors should have a diversified portfolio. ABBV, JNJ, LLY, and MRK all reached 52-week high on Friday.
0 · Reply
itamardrori
itamardrori Jun. 27 at 8:57 PM
$ABBV cup & handle setup. Trigger: $227.55. My scanner flagged it pre-open. Watching the level.
0 · Reply
WhaleTracker_
WhaleTracker_ Jun. 27 at 2:10 PM
This week’s tape rotation is pretty clear - AI and semis took a breather, while defensives quietly led. 1-week returns: $ABBV +17% (AbbVie) $MRK +13% (Merck) $JNJ +12% (Johnson & Johnson) $DHR +11% (Danaher) $LLY +10% (Eli Lilly) What stands out isn’t just performance, but leadership shifting into healthcare while high-beta growth cooled off. This kind of rotation usually says more about positioning stress than any single macro headline - when crowded trades unwind, capital doesn’t disappear, it just moves.
0 · Reply
Buffet87
Buffet87 Jun. 27 at 1:38 PM
$ABBV fancy buying $SLS
0 · Reply
Latest News on ABBV
AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 2 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 4 days ago

AbbVie's $11 Billion Immunology Bet

APGE


Apogee Therapeutics moved to No Rating at BofA

2026-06-23T11:29:50.000Z - 5 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE


AbbVie price target raised to $273 from $265 at Canaccord

2026-06-23T11:04:51.000Z - 5 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE


AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:24:35.000Z - 5 days ago

AbbVie announces European Commission approval for Skyrizi


AbbVie announces European Commission approval of Maviret

2026-06-23T10:00:54.000Z - 5 days ago

AbbVie announces European Commission approval of Maviret


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 6 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 6 days ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 6 days ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 6 days ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 6 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie to acquire Apogee Therapeutics for $10.9B in cash

2026-06-22T11:15:52.000Z - 6 days ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 6 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 10 days ago

AbbVie Declares Quarterly Dividend


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 4 weeks ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie Transcript: AGM 2026


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results


US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment


Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 2 months ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation


Pravo_Koirala
Pravo_Koirala Jun. 28 at 4:34 PM
📊 $ABBV — WEDGE BREAK ON A VOLUME EXPLOSION | 1W Weekly close $253.35, +𝟭𝟳% on the week. This is a structural break, not a drift. 💥 THE VOLUME TELL 𝟴𝟳.𝟱𝗠 shares — the largest volume bar on the entire chart, by a wide margin. A breakout this size on volume this heavy is the confirmation you want. Wedge breaks that fail usually fail on weak volume. This one didn't. 🔓 THE BREAK Price broke clean out of the descending consolidation wedge (converging trendlines off the Oct-2025 $239 high). The candle cleared: ▪ the wedge upper rail ▪ the CHoCH ▪ the Weak High (~$253) ▪ into PREMIUM (above the 1.236 fib / $258 zone) 🪞 Structure flipped. Equilibrium reclaimed, premium entered, momentum confirming. 📐 THE MEASURED MOVE Wedge height ≈ $50 (range low ~$188 → high ~$239). Projected from the ~$253 breakout → ~$𝟯𝟬𝟯. The kicker: that lines up almost exactly with the 𝟭.𝟳𝟴𝟲 fib ($303.11) AND your $302.98 horizontal. Measured move + fib extension agree = the target isn't arbitrary. That's the confluence that matters. 📈 THE PATH ▪ Next resistance: 1.236 $258 → 1.382 $270 → 1.5 $280 → 1.618 $289 → 𝗧𝗔𝗥𝗚𝗘𝗧 1.786 $303 ▪ RSI 67, rising, crossed its signal — momentum behind it, NOT yet overbought (sub-70 leaves room) 🪞 Clean ladder of fib resistance into $303. Each level is a checkpoint, not a wall — but watch $258 (premium entry) for the first pause. 🛡 INVALIDATION A weekly close back INSIDE the wedge / below the breakout (~$240, the prior range high) negates it. That's the line — below it, the break failed and it's a fakeout retest. 🪞 THE READ This is a textbook setup: multi-month wedge, explosive volume break, measured move and fib extension agreeing on ~$303, RSI confirming with room left. The volume is what separates this from a fade — 87M doesn't show up on noise. I want to see it HOLD above the breakout (~$240) on any pullback; a retest that holds is the highest-quality entry. Don't chase the +17% candle extended — let it confirm the breakout as support, then ride the ladder to $303. ⚔ Volume confirmed the break. Measured move = $303. Let it
0 · Reply
PLTRLONGDONG
PLTRLONGDONG Jun. 28 at 4:12 PM
$ABCL i think its more due to Tcell work with $ABBV but I’m sure $JAZZ saw promise with 635 and 575
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 28 at 2:21 AM
$RVMD $SLS $ABBV $MRK Part 4. Merck & Co. (MRK) held advanced acquisition talks to buy Revolution Medicines (RVMD) for roughly $28 billion to $32 billion. However, the deal fell apart in late January 2026 when the two companies could not agree on a final purchase price. Earlier in January 2026, AbbVie (ABBV) was also rumored by the Wall Street Journal to be nearing a deal to acquire Revolution Medicines.$RVMD MC now is $39 Billion any big pharmaceutical have to pay close to $70 Billion to buy them out. I don’t think big pharmaceutical will make the same mistake by trying to tame the$SLS Beast and bidding war is here now before the whole world find out about the one ☝️ and only off the shelf, 0 Toxicity platform GPS with Ad Infinitum dosage CURATIVE cancer platform that can make the most lethal cancers on the planet Dormant and further CURATIVE. I wouldn’t be surprised if we get a T1 halt on Sellas one of these days and company is BO outright. ✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 28 at 12:59 AM
$SLS With the 80th Event Now Truly Imminent, after 5 years - the Share Price / Market Action Sure is doing what you would expect -if- the people* who really understand the drug space are confident in Gps Success. * $ABBV $RHHBY who own the Azacitidine Venetoclax - BAT for Control Arm Patients * Fund Analysts Buying the Share Price Up - Paying Attention to every Last Scrap of Published Trial Data and any information relative and pertinent - etc., etc., etc. ie BAT Failing 3 AML Remission Maintenance Trials - Gps Proven Effective in 2 Phase 2 AML Remission Maintenance trials w 2x and 4x+ Statistically Significant Results - IDMC UNBLINDING ACTUAL Phase 3 MOS and Immune Response Data - 80% IR in the P3 / vs 64% in the P2 - IR is Dir Correlated w Survival. Smarter Money than US Knows.
0 · Reply
KryptonResearch
KryptonResearch Jun. 27 at 10:14 PM
While markets are extremely focused on the inputs to the AI trade (and for good reason, as this is where the capital is flowing at the present moment). We take a look at the flip side of the AI trade. Those using AI to accelerate their businesses. Today’s investment is one of our favorites. A great business and revolutionary technology, but more importantly, one that is going to transform the lives of billions. $LLY $NVO $ABBV $PFE $JNJ Take a read: https://kryptonresearch.substack.com/p/blood-money
0 · Reply
FibonacciTrader_
FibonacciTrader_ Jun. 27 at 10:03 PM
Rotation is doing exactly what it usually does late-cycle- money stops chasing momentum and starts hiding in defensives with visible cash flows. This week the tape flipped hard: $ABBV +17% | pharma leadership catching bid on defensive + yield rotation $MRK +13% | large-cap healthcare strength as risk appetite fades $JNJ +12% | classic safety trade back in favor $DHR +11% | life sciences tools seeing steady institutional demand $LLY +10% | still strong structurally, but now part of broader defensive bid Meanwhile semis are cooling as AI beta unwinds from stretched positioning. This isn’t “AI is dead” pricing. It’s capital rotating from narrative to stability. When healthcare leads and semis lag, the market is telling you one thing: risk is being reduced, not added
0 · Reply
bzb711
bzb711 Jun. 27 at 10:03 PM
$ABBV Now money flows to Healthcare from Tech, that’s why investors should have a diversified portfolio. ABBV, JNJ, LLY, and MRK all reached 52-week high on Friday.
0 · Reply
itamardrori
itamardrori Jun. 27 at 8:57 PM
$ABBV cup & handle setup. Trigger: $227.55. My scanner flagged it pre-open. Watching the level.
0 · Reply
WhaleTracker_
WhaleTracker_ Jun. 27 at 2:10 PM
This week’s tape rotation is pretty clear - AI and semis took a breather, while defensives quietly led. 1-week returns: $ABBV +17% (AbbVie) $MRK +13% (Merck) $JNJ +12% (Johnson & Johnson) $DHR +11% (Danaher) $LLY +10% (Eli Lilly) What stands out isn’t just performance, but leadership shifting into healthcare while high-beta growth cooled off. This kind of rotation usually says more about positioning stress than any single macro headline - when crowded trades unwind, capital doesn’t disappear, it just moves.
0 · Reply
Buffet87
Buffet87 Jun. 27 at 1:38 PM
$ABBV fancy buying $SLS
0 · Reply
Br331
Br331 Jun. 27 at 1:34 PM
$ABBV 700 on deck
0 · Reply
Scanlz
Scanlz Jun. 27 at 1:27 PM
$ABBV $500 BEOY
1 · Reply
Bjorgum
Bjorgum Jun. 27 at 1:05 PM
Healthcare starting to show real underlying strength here. Breakouts across $XBI and even $XLV approaching a key breakout level with breakouts on $JNJ and $ABBV. Even $GILD looks like it’s finding support after a long-term cup/base breakout. With semis extended, this could be an important defensive rotation to watch.
0 · Reply
bzb711
bzb711 Jun. 27 at 4:41 AM
$ABBV Long ABBV and LLY. Got both in my portfolio.
0 · Reply
topstockalerts
topstockalerts Jun. 27 at 2:15 AM
Healthcare stocks attracted strong investor demand this week as money rotated out of technology shares, pushing AbbVie, Eli Lilly and Johnson & Johnson to record closing highs. The sector benefited from its defensive characteristics and confidence in the long-term growth prospects of leading pharmaceutical companies. AbbVie's shares received an additional boost after the company announced plans to acquire Apogee Therapeutics, strengthening its drug development pipeline. According to RBC Capital Markets, AbbVie, Eli Lilly and Johnson & Johnson have largely avoided the operational setbacks that forced several competitors to restructure, while making strategic acquisitions that enhance future growth opportunities. Other biopharmaceutical companies, including Regeneron, Sanofi, Moderna and Absci, also advanced, lifting healthcare-focused ETFs as investors sought stability amid weakness in technology stocks and growing uncertainty around AI-related valuations. $ABBV $APGE $REGN $SNY $LLY
0 · Reply
CNMI670
CNMI670 Jun. 27 at 1:10 AM
ACOG - Alpha Cognition: Opaleye Mgmt accumulation with Zunveyl post-approval RESOLVE Phase 4 data due 2027 - study designed to further evaluate the safety and tolerability profile of Zunveyl in patients with Alzheimer's disease. $LLY $BMY $ABBV $PFE $MRK
0 · Reply
MarketMaestro1
MarketMaestro1 Jun. 26 at 11:47 PM
Nobody signaled $ABBV for today except me 🚨 (300% later ❤️‍🔥) No one alerted $BMY today except me 🚨 (100% gainer ☢️) All for completely free, with timestamps. Nobody is doing what I am doing—and it’s not even close. The next list is about to be released! Are you going to miss out again? I’m not financially struggling, so I choose to share it for free. NFA
0 · Reply
BullFunds
BullFunds Jun. 26 at 10:34 PM
$LLY was solid rock on update $VRDN will be too FDA APPROVAL NEWS AFTER HOURS $ABBV GOT A FDA NEWS TOO
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 26 at 9:42 PM
$TNXP buy $BMY hold $ABBV hold? $NVS sell 🤫 ☘️ 🚀
0 · Reply
PanicSeller8
PanicSeller8 Jun. 26 at 8:39 PM
$ABBV Crazy close.
0 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Jun. 26 at 8:21 PM
$ABBV what was that last second pump
0 · Reply
Gramma
Gramma Jun. 26 at 8:10 PM
$ABBV On a tear lately had for many years and great divy!!!
3 · Reply